Ansell (ASX: ANN) $38.24
ANN +9.57%: Posted a strong FY26 result, beating expectations on both revenue and earnings while demonstrating that pricing actions have successfully offset tariff and geopolitical pressures.
Ansell (ANN)
ANN $46.31
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 46.31
- Change
- ▼ -0.64 (-1.36)
- Bid / Ask
- 46.30 - 46.31
- Volume
- 199,181
- Turnover
- 9,266,151
- Open
- 46.89
- Day Range
- 46.31 - 47.17
- VWAP
- 46.52
- Prev Close
- 46.95
- Last Trade
- 13/11 4:16pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 140,313,831
- NTA/Share
- 2.64
- Last Dividend
- 0.58
- Dividend Ex Date
- 31 AUG 2026
- Dividend Pay Date
- 17 SEP 2026
Current (USD) · FY2026
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 2,140.20
- EBITDA
- 400.20
- Profit
- 208.60
- Earnings Per Share (EPS)
- 1.45
- Dividend Per Share (DPS)
- 0.53
- Yield %
- 2.06
- Market Cap
- 6,516.81
- Price to Earnings Ratio (P/E)
- 21.71
Estimates (AUD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 2,249.10
- EBITDA
- 409.00
- Profit
- 269.70
- Earnings Per Share (EPS)
- 1.98
- Dividend Per Share (DPS)
- 0.83
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Fairly valued
- Economic Moat
- None
- Financial Health
- Strong
- Uncertainty
- Low
Morningstar Quantitative Rating as of 12 NOV 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 41.29 Fair value 45.54 One-star price 50.23
Morningstar Quantitative Rating as of 12 NOV 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 45.54
- Price / Fair Value
- 1.03
- Valuation
- Fairly valued
- Uncertainty
- Low
Morningstar Quantitative Rating as of 12 NOV 2026. The slider runs from the five-star price (41.29) to the one-star price (50.23).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): AUD/USD |
| Exchange Rate: 1.4738 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 46.31 |
| Price - 12 month high | 47.19 |
| Price - 12 month low | 25.05 |
| Pricing date | 12 NOV 2026 |
| Volume - avg. trading volume for the last ten days | 0.65 |
| Market capitalization | 6,516.81 |
| 12 Month High price date | 12 NOV 2026 |
| 12 Month Low price date | 18 MAY 2026 |
| Volume - avg. trading volume for the last 3 months | 0.65 |
| Price - 1 Day % Change | -1.36% |
| Price - 13 week price percent change | 33.88% |
| Price - 26 week price percent change | 80.97% |
| Price - 5 Day % Change | 1.74% |
| Price - 52 week price percent change | 26.63% |
| Price - YTD price percent change | 32.28% |
| Price % Change Month To Date | 2.57% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 1.451 |
| EPS excluding extraordinary items - trailing 12 month | 1.451 |
| EPS Normalized - most recent fiscal year | 1.477 |
| Revenue/share - most recent fiscal year | 14.887 |
| Revenue/share - trailing 12 month | 14.887 |
| Book value per share - most recent fiscal year | 14.284 |
| Book value per share - most recent half-year | 14.284 |
| Book value (tangible) per share - most recent fiscal year | 2.636 |
| Book value (tangible) per share - most recent half-year | 2.636 |
| Cash per share - most recent fiscal year | 1.765 |
| Cash per share - most recent half-year | 1.765 |
| Cash Flow per share - most recent fiscal year | 2.380 |
| Cash Flow per share - trailing 12 month | 2.380 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.956 |
| EBITD per share - trailing 12 month | 2.784 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 1.460 |
| EPS Basic excluding extraordinary items - trailing 12 month | 1.460 |
| EPS including extraordinary items - most recent fiscal year | 1.460 |
| EPS including extraordinary items - trailing 12 month | 1.460 |
| Free Cash Flow per share - trailing 12 month | 2.039 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 21.62 |
| P/E Normalized, most recent fiscal year | 21.24 |
| Price to sales - most recent fiscal year | 2.11 |
| Price to Tangible Book - most fiscal year | 13.20 |
| Price to Free Cash Flow per Share - most recent fiscal year | 15.39 |
| Price to Cash Flow per share - trailing 12 month | 13.18 |
| Price to Book - most recent fiscal year | 2.23 |
| P/E excluding extraordinary items high, trailing 12 months | 34.90 |
| P/E excluding extraordinary items low, trailing 12 months | 17.36 |
| Net Debt, LFI | 583.00 |
| Net Debt, LFY | 510.60 |
| Dividend Yield - 5 Year Average | 2.55% |
| Dividend Yield - indicated annual dividend divided by closing price | 2.06% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 2.06% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 293.10 |
| LT debt/equity - most recent fiscal year | 33.84% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 37.42% |
| LT debt/equity - most recent half-year | 37.53% |
| Total debt/total equity - most recent half-year | 41.63% |
| Free Cash Flow - trailing 12 month | 293.10 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 2,140.20 |
| Revenue - trailing 12 month | 2,140.20 |
| EBITD - most recent fiscal year | 400.20 |
| EBITD - trailing 12 month | 400.20 |
| Earnings before taxes - most recent fiscal year | 279.60 |
| Earnings before taxes - trailing 12 month | 279.60 |
| Net Income available to common - most recent fiscal year | 208.60 |
| Net Income available to common - trailing 12 months | 208.60 |
| Earnings before taxes Normalized - most recent fiscal year | 298.90 |
| Net Income Available to Common, Normalized - most recent fiscal year | 212.30 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 1.48 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 9.79% |
| Net Profit Margin % - trailing 12 month | 9.79% |
| Operating margin - 1st historical fiscal year | 14.98% |
| Operating margin - trailing 12 month | 14.98% |
| Pretax margin - trailing 12 month | 13.06% |
| Pretax margin - 1st historical fiscal year | 13.06% |
| Operating Margin - 5 year average | 11.36% |
| Pretax Margin - 5 year average | 9.82% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 8.20% |
| Free Operating Cash Flow/Revenue, TTM | 13.70% |
| Net Profit Margin - 5 year average | 7.40% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 6.33% |
| Return on average assets - trailing 12 month | 6.33% |
| Return on average equity - most recent fiscal year | 10.61% |
| Return on average equity - trailing 12 month | 10.61% |
| Return on average assets - 5 year average | 5.04% |
| Return on average equity - 5 year average | 8.44% |
| Net Income/employee - most recent fiscal year | — |
| Revenue/employee - most recent fiscal year | — |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 1.09% |
| EPS growth rate, 5 year | -5.21% |
| Growth rate% - dividend, 3 year | 0.82% |
| Revenue/share (5 yr growth) | -0.90% |
| Growth rate% - Revenue, 3 year | 8.95% |
| Growth rate% - EPS, 3 year | 7.53% |
| Book value per share growth rate, 5 year | 3.24% |
| Capital Spending growth rate, 5 year | -9.94% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | -0.09% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (AUD, millions except per share)
| Actuals | Estimates | |||||||
| 2026 | 2027 | 2028 | 2029 | |||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | JUN 22 | JUN 23 | JUN 24 | JUN 25 | JUN 26 |
| Fiscal year: | 2022 | 2023 | 2024 | 2025 | 2026 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
| DATE | TIME | HEADING | PAGES |
| Price sensitive |
Opinion
Ansell Ltd (ASX: ANN) $32.55
Personal protective equipment (PPE) provider ANN has rallied strongly from its May low driven by a combination of improving sentiment, confidence in the company’s resilient earnings outlook and ongoing share buybacks. With around 45% of FY25 revenue generated in the US, the business remains well leveraged to its largest market. Pleasingly, the US division performed in line with expectations in 1H26, successfully passing through tariff-related cost increases, despite some softness in tariff-exposed end markets.
Ansell Ltd (ASX: ANN) $30.24
Personal protective equipment (PPE) provider ANN has rallied strongly from its May low driven by a combination of improving sentiment, confidence in the company's resilient earnings outlook and ongoing share buybacks, which have helped support the stock after a tough 12 months. With Earnings Per Share (EPS) set to lift by ~20% from FY25 to FY27 the recent downside re-rating feels unjustified, although the stock is now only trading ~10% below its long-term valuation.
Ansell Ltd (ANN) $33.91
Personal protective equipment (PPE) business ANN popped +4.5% through yesterday's session, its best gain in 7 weeks, helped by an upgrade from Jefferies, although the stock is still flat year-to-date as it struggled for direction.
Ansell Ltd (ANN) $31.41
Safety and protection company ANN is no stranger to bad results having delivered a few in its time. Its movements over the last 6 months haven’t been good and its “bounce” fairly muted but combined with its history and more than 40% revenue from the US, we see this as a risk. The stock made a new high in February after the personal protective equipment (PPE) provider delivered strong 1H revenue and upgraded its FY25 earnings guidance.
Ansell (ANN) $37.77
ANN +8.13% moved to a 3 year high as the personal protective equipment (PPE) provider delivered strong 1H revenue and upgraded its FY25 earnings guidance.
Ansell Ltd (ANN) $29.47
ANN’s shares jumped +8.9% on Tuesday after the medical glovemaker forecast EPS for the full year of $1.07-$1.27, ahead of consensus on in-line revenue but lower operating costs.
Ansell Ltd (ANN) $24.26
ANN delivered a relatively benign report earlier this week, a big win compared to the past few years! While de-stocking dynamics continue to remain an issue, it has been interesting to see ANN recover this week after delivering revenue, EBIT and EPS all below consensus
Ansell Ltd (ANN) $24.79
ANN was the best performer of the major healthcare names yesterday, and although the +2.8% rise wasn’t vaguely as dramatic as the crash by NAN, it was another example of an underperformer over recent years attracting some buying. The company downgraded mid-last year, compounding similar moves in 2022 and until they start delivering buying feels like “bottom picking” for the sake of it.
Ansell Ltd (ANN) $22.28
When you’re cold you’re cold and that’s definitely been the case for both Ansell (ANN) and the Healthcare Sector in 2023 e.g. the Healthcare Index is -5.2% year-to-date compared to the Tech Sector which is up over 30%!
Action
Updated
24/08/2026
16:51
ANN
Updated 24/08/2026 16:51
MM is positive toward ANN
Updated
07/07/2026
09:36
ANN
Updated 07/07/2026 09:36
MM is bullish towards ANN around $32
Updated
25/06/2026
10:35
ANN
Updated 25/06/2026 10:35
MM is bullish towards ANN around $30
Updated
16/10/2025
08:53
ANN
Updated 16/10/2025 08:53
MM is neutral towards ANN
Updated
21/08/2025
09:37
ANN
Updated 21/08/2025 09:37
MM is neutral towards ANN around $31
Updated
10/02/2025
17:37
ANN
Updated 10/02/2025 17:37
MM is cautiously bullish ANN
Updated
21/08/2024
13:05
ANN
Updated 21/08/2024 13:05
MM is cautiously bullish towards ANN
Updated
20/06/2024
10:11
ANN
Updated 20/06/2024 10:11
MM is neutral to cautiously bullish towards ANN
Updated
27/02/2024
11:13
ANN
Updated 27/02/2024 11:13
MM is neutral to cautiously bullish towards ANN
Updated
25/01/2024
16:40
ANN
Updated 25/01/2024 16:40
MM is neutral to cautiously bullish ANN below $25
Business Summary
Ansell is a leading supplier of protective gloves and other wearable PPE for use in healthcare and industrial settings, each contributing about 50% of revenue. Industrial contributes slightly higher EBIT owing to higher margins. The company holds more than 500 patents, and most sales come from its key branded product ranges. Products are sold in about 100 countries, mostly via distributors. Approximately half of revenue is from North America, and about one-third is from Europe, the Middle East, and Asia. Latin America and Asia-Pacific each contribute about 10%.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
